Sign in or create an account to add this stock to your watchlist.
About Audentes Therapeutics (NASDAQ:BOLD)
Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. Audentes Therapeutics, Inc. has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. The company was founded in 2012 and is headquartered in San Francisco, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BOLD
CUSIPN/A
Phone415-818-1001
Debt
Debt-to-Equity RatioN/A
Current Ratio20.44
Quick Ratio20.45
Price-To-Earnings
Trailing P/E Ratio-10.81
Forward P/E Ratio-11.03
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value($5.89) per share
Price / Book-6.20
Profitability
EPS (Most Recent Fiscal Year)($3.40)
Net Income$-90,230,000.00
Net MarginsN/A
Return on EquityN/A
Return on Assets-41.55%
Miscellaneous
Employees152
Outstanding Shares36,740,000
Audentes Therapeutics (NASDAQ:BOLD) Frequently Asked Questions
What is Audentes Therapeutics' stock symbol?
Audentes Therapeutics trades on the NASDAQ under the ticker symbol "BOLD."
How were Audentes Therapeutics' earnings last quarter?
Audentes Therapeutics (NASDAQ:BOLD) released its earnings results on Wednesday, May, 9th. The biotechnology company reported ($0.74) EPS for the quarter, beating the Zacks' consensus estimate of ($0.81) by $0.07. View Audentes Therapeutics' Earnings History.
When is Audentes Therapeutics' next earnings date?
What price target have analysts set for BOLD?
10 brokers have issued twelve-month target prices for Audentes Therapeutics' stock. Their forecasts range from $23.00 to $56.00. On average, they expect Audentes Therapeutics' share price to reach $37.25 in the next year. View Analyst Ratings for Audentes Therapeutics.
What are Wall Street analysts saying about Audentes Therapeutics stock?
Here are some recent quotes from research analysts about Audentes Therapeutics stock:
- 1. Mizuho analysts commented, "We came away very encouraged by the data which showed continued improvements in the first cohort of patients, as well as early positive data in the expansion cohort. We see a stronger probability of success for the AT-132 program and we therefore raise our price target from $26 to $38 to reflect the higher PoS. We maintain our Neutral rating as we believe the shares are fairly priced." (5/21/2018)
- 2. Raymond James analysts commented, "We are maintaining our Market Perform rating on BOLD. Therapy (ASGCT) annual meeting, the company provided an update on the ongoing Phase I/II ASPIRO study of AT132 for X-linked myotubular myopathy (XLMTM). By comparing the results of the ASPIRO study and those of the INCEPTUS trial, in our opinion, the totality of the updated data continues to suggest that AT132 provides a significant benefit to patients suffering with XLMTM, which may lead to an accelerated regulatory pathway. That said, we remain cautiously optimistic about the commercial prospect of this product given rare nature of the disease being pursued." (5/17/2018)
- 3. William Blair analysts commented, "We view the update as a positive and initial safety concerns as largely overblown, particularly when compared with the data from the INCEPTUS run-in study and noting that the majority were in a single patient who had previously experienced several pneumonia episodes, a tachycardic event in the run-in trial, and was on 24 hours of invasive ventilation at baseline." (5/17/2018)
- 4. According to Zacks Investment Research, "Audentes Therapeutics, Inc. is a biotechnology company which focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases. The company's product pipeline consists of AT132 for the treatment of X-linked myotubular myopathy; AT342 for the treatment of crigler-najjar syndrome type 1; AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia and AT982 for the treatment of pompe disease, which are in pre-clinical trial stage. Audentes Therapeutics, Inc. is based in San Francisco, California. " (3/13/2018)
Who are some of Audentes Therapeutics' key competitors?
Some companies that are related to Audentes Therapeutics include arGEN-X BV (ARGX), CRISPR Therapeutics (CRSP), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Halozyme Therapeutics (HALO), Atara Biotherapeutics (ATRA), Aerie Pharmaceuticals (AERI), Denali Therapeutics (DNLI), Repligen (RGEN), Momenta Pharmaceuticals (MNTA), Acceleron Pharma (XLRN), Editas Medicine (EDIT), Sangamo Therapeutics (SGMO), REGENXBIO (RGNX) and Iovance Biotherapeutics (IOVA).
Who are Audentes Therapeutics' key executives?
Audentes Therapeutics' management team includes the folowing people:
- Mr. Matthew R. Patterson, Co-Founder, CEO, Pres & Director (Age 46)
- Mr. Thomas P. Soloway, CFO and Sr. VP (Age 51)
- Ms. Natalie C. Holles, Chief Operating Officer and Sr. VP (Age 45)
- Dr. John T. Gray Ph.D., Chief Scientific Officer and Sr. VP (Age 55)
- Ms. Dawn Blessing, VP of Corp. Devel.
When did Audentes Therapeutics IPO?
(BOLD) raised $75 million in an initial public offering (IPO) on Wednesday, July 20th 2016. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Company and Piper Jaffray served as the underwriters for the IPO and Wedbush PacGrow was co-manager.
Has Audentes Therapeutics been receiving favorable news coverage?
News headlines about BOLD stock have trended somewhat positive on Thursday, Accern reports. The research group ranks the sentiment of news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Audentes Therapeutics earned a media sentiment score of 0.15 on Accern's scale. They also assigned press coverage about the biotechnology company an impact score of 46.05 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
Who are Audentes Therapeutics' major shareholders?
Audentes Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.34%), Sofinnova Ventures Inc (3.76%), Redmile Group LLC (3.56%), Rock Springs Capital Management LP (1.54%), Victory Capital Management Inc. (1.49%) and Lord Abbett & CO. LLC (0.91%). Company insiders that own Audentes Therapeutics stock include 5Am Partners Iii, Llc, David Nagler, James E Flynn, Louis G Lange, Mary Newman, Matthew R Patterson, Orbimed Advisors Llc, Suyash Prasad and Versant Ventures Iv, Llc. View Institutional Ownership Trends for Audentes Therapeutics.
Which major investors are selling Audentes Therapeutics stock?
BOLD stock was sold by a variety of institutional investors in the last quarter, including Artal Group S.A., Opaleye Management Inc. and JPMorgan Chase & Co.. Company insiders that have sold Audentes Therapeutics company stock in the last year include David Nagler, Louis G Lange, Mary Newman, Matthew R Patterson, Orbimed Advisors Llc and Suyash Prasad. View Insider Buying and Selling for Audentes Therapeutics.
Which major investors are buying Audentes Therapeutics stock?
BOLD stock was acquired by a variety of institutional investors in the last quarter, including Sofinnova Ventures Inc, BlackRock Inc., Victory Capital Management Inc., Redmile Group LLC, Foresite Capital Management III LLC, Wells Fargo & Company MN, Millennium Management LLC and Lord Abbett & CO. LLC. Company insiders that have bought Audentes Therapeutics stock in the last two years include 5Am Partners Iii, Llc, James E Flynn, Orbimed Advisors Llc and Versant Ventures Iv, Llc. View Insider Buying and Selling for Audentes Therapeutics.
How do I buy shares of Audentes Therapeutics?
Shares of BOLD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Audentes Therapeutics' stock price today?
One share of BOLD stock can currently be purchased for approximately $36.50.
How big of a company is Audentes Therapeutics?
Audentes Therapeutics has a market capitalization of $1.39 billion. The biotechnology company earns $-90,230,000.00 in net income (profit) each year or ($3.40) on an earnings per share basis. Audentes Therapeutics employs 152 workers across the globe.
How can I contact Audentes Therapeutics?
Audentes Therapeutics' mailing address is 600 CALIFORNIA ST. 17TH FLOOR, SAN FRANCISCO CA, 94108. The biotechnology company can be reached via phone at 415-818-1001 or via email at [email protected]
MarketBeat Community Rating for Audentes Therapeutics (BOLD)
MarketBeat's community ratings are surveys of what our community members think about Audentes Therapeutics and other stocks. Vote "Outperform" if you believe BOLD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BOLD will underperform the S&P 500 over the long term. You may vote once every thirty days.
Audentes Therapeutics (NASDAQ:BOLD) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
10 Wall Street analysts have issued ratings and price targets for Audentes Therapeutics in the last 12 months. Their average twelve-month price target is $37.25, suggesting that the stock has a possible upside of 2.05%. The high price target for BOLD is $56.00 and the low price target for BOLD is $23.00. There are currently 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.80 | 2.80 | 2.78 | 2.80 |
| Ratings Breakdown: | 0 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $37.25 | $35.3750 | $35.3750 | $28.00 |
| Price Target Upside: | 2.05% upside | 2.39% downside | 7.85% upside | 8.78% upside |
Audentes Therapeutics (NASDAQ:BOLD) Consensus Price Target History
Audentes Therapeutics (NASDAQ:BOLD) Analyst Ratings History
Show:
(Data available from 5/24/2016 forward)
Audentes Therapeutics (NASDAQ:BOLD) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Audentes Therapeutics (NASDAQ BOLD) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 6.60%
Institutional Ownership Percentage: 95.29%
Audentes Therapeutics (NASDAQ BOLD) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/21/2018 | Matthew R Patterson | CEO | Sell | 20,300 | $38.15 | $774,445.00 | 13,600 |  |
| 4/2/2018 | Matthew R Patterson | CEO | Sell | 700 | $30.01 | $21,007.00 | 700 | |
| 3/29/2018 | Suyash Prasad | VP | Sell | 7,800 | $30.03 | $234,234.00 | 7,800 | |
| 3/26/2018 | Louis G Lange | Director | Sell | 48,000 | $28.89 | $1,386,720.00 | 414,231 | |
| 3/26/2018 | Suyash Prasad | VP | Sell | 1,900 | $30.00 | $57,000.00 | 1,900 | |
| 3/15/2018 | Mary Newman | SVP | Sell | 10,000 | $30.36 | $303,600.00 | 4,076 | |
| 3/12/2018 | Orbimed Advisors Llc | Major Shareholder | Sell | 156,431 | $34.97 | $5,470,392.07 | | |
| 3/8/2018 | Orbimed Advisors Llc | Major Shareholder | Sell | 58,428 | $34.06 | $1,990,057.68 | | |
| 3/6/2018 | Orbimed Advisors Llc | Major Shareholder | Sell | 433,210 | $35.11 | $15,210,003.10 | | |
| 3/2/2018 | Orbimed Advisors Llc | Major Shareholder | Sell | 421,638 | $35.17 | $14,829,008.46 | | |
| 12/22/2017 | Louis G Lange | Director | Sell | 18,000 | $30.88 | $555,840.00 | | |
| 12/1/2017 | Suyash Prasad | VP | Sell | 8,000 | $28.53 | $228,240.00 | | |
| 11/16/2017 | Mary Newman | SVP | Sell | 10,000 | $26.84 | $268,400.00 | | |
| 10/2/2017 | Matthew R Patterson | CEO | Sell | 25,000 | $27.92 | $698,000.00 | | |
| 9/29/2017 | Louis G Lange | Director | Sell | 11,000 | $28.35 | $311,850.00 | 441,555 | |
| 9/29/2017 | Orbimed Advisors Llc | Major Shareholder | Sell | 672,000 | $28.25 | $18,984,000.00 | | |
| 9/27/2017 | David Nagler | SVP | Sell | 3,750 | $30.00 | $112,500.00 | 3,750 | |
| 9/25/2017 | Louis G Lange | Director | Sell | 18,000 | $28.32 | $509,760.00 | 453,393 | |
| 9/18/2017 | Matthew R Patterson | CEO | Sell | 10,000 | $25.06 | $250,600.00 | 1,542 | |
| 9/15/2017 | David Nagler | SVP | Sell | 3,750 | $25.00 | $93,750.00 | 3,750 | |
| 9/7/2017 | Orbimed Advisors Llc | Major Shareholder | Sell | 5,000 | $22.35 | $111,750.00 | | |
| 9/1/2017 | Suyash Prasad | VP | Sell | 8,000 | $21.44 | $171,520.00 | 8,000 | |
| 8/24/2017 | Mary Newman | SVP | Sell | 10,000 | $20.00 | $200,000.00 | 10,000 | |
| 7/13/2017 | Matthew R Patterson | CEO | Sell | 15,000 | $20.00 | $300,000.00 | | |
| 7/12/2017 | Matthew R Patterson | CEO | Sell | 2,850 | $20.00 | $57,000.00 | | |
| 6/26/2017 | Louis G Lange | Director | Sell | 15,000 | $19.78 | $296,700.00 | 470,799 | |
| 4/24/2017 | 5Am Partners Iii, Llc | Insider | Buy | 172,413 | $14.50 | $2,499,988.50 | | |
| 7/25/2016 | James E Flynn | Insider | Buy | 400,000 | $15.00 | $6,000,000.00 | | |
| 7/25/2016 | Orbimed Advisors Llc | Director | Buy | 33,334 | $15.00 | $500,010.00 | | |
| 7/25/2016 | Versant Ventures Iv, Llc | Major Shareholder | Buy | 35,000 | $15.00 | $525,000.00 | | |
(Data available from 1/1/2013 forward)
Audentes Therapeutics (NASDAQ BOLD) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Insider Selling: Audentes Therapeutics (BOLD) CEO Sells 20,300 Shares of Stock
www.americanbankingnews.com - May 23 at 7:18 PM |
| Comparing Audentes Therapeutics (BOLD) and BioCryst Pharmaceuticals (BCRX)
www.americanbankingnews.com - May 22 at 10:03 AM |
| Audentes Therapeutics (BOLD) Rating Reiterated by Mizuho
www.americanbankingnews.com - May 21 at 9:55 AM |
 | EIGR Soars On Progeria Deal, BOLD Investors Emboldened, BDSI's Cash Strengthens
www.nasdaq.com - May 18 at 10:56 AM |
| Notable Thursday Option Activity: WFC, BOLD, AXTA
www.nasdaq.com - May 17 at 4:17 PM |
| Audentes Therapeutics (BOLD) PT Raised to $40.00 at HC Wainwright
www.americanbankingnews.com - May 17 at 3:27 PM |
| Audentes Therapeutics (BOLD) Receives Hold Rating from Raymond James
www.americanbankingnews.com - May 17 at 2:51 PM |
| Audentes Therapeutics' (BOLD) Buy Rating Reaffirmed at William Blair
www.americanbankingnews.com - May 17 at 11:45 AM |
 | Audentes reports positive results from study of AT132 in XLMTM; shares up 7%
seekingalpha.com - May 16 at 4:07 PM |
 | Audentes Therapeutics (BOLD) Announces Continuing Positive Data from First Dose Cohort of ASPIRO
www.streetinsider.com - May 16 at 4:07 PM |
 | Audentes Announces Continuing Positive Data from First Dose Cohort of ASPIRO, a Phase 1/2 Clinical Trial of AT132 in Patients With X-Linked Myotubular Myopathy
finance.yahoo.com - May 16 at 4:07 PM |
| Audentes Therapeutics (BOLD) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - May 16 at 1:24 AM |
| Q2 2018 Earnings Forecast for Audentes Therapeutics Issued By William Blair (BOLD)
www.americanbankingnews.com - May 14 at 2:38 AM |
| Equities Analysts Set Expectations for Audentes Therapeutics' Q2 2018 Earnings (BOLD)
www.americanbankingnews.com - May 14 at 2:38 AM |
| Q2 2018 Earnings Forecast for Audentes Therapeutics Issued By Piper Jaffray (BOLD)
www.americanbankingnews.com - May 14 at 2:38 AM |
| Audentes Therapeutics: Key Program Updates
seekingalpha.com - May 12 at 10:37 AM |
| Audentes Therapeutics (BOLD) Given Hold Rating at Raymond James
www.americanbankingnews.com - May 11 at 7:49 PM |
| Analysts Expect Audentes Therapeutics (BOLD) Will Announce Earnings of -$0.79 Per Share
www.americanbankingnews.com - May 11 at 5:36 PM |
| Audentes Therapeutics (BOLD) Forecasted to Earn FY2020 Earnings of ($3.15) Per Share
www.americanbankingnews.com - May 11 at 11:47 AM |
| Edited Transcript of BOLD earnings conference call or presentation 9-May-18 8:30pm GMT
finance.yahoo.com - May 11 at 10:55 AM |
| Audentes Therapeutics (BOLD) Given a $37.00 Price Target at HC Wainwright
www.americanbankingnews.com - May 10 at 1:28 PM |
| Wedbush Reaffirms Outperform Rating for Audentes Therapeutics (BOLD)
www.americanbankingnews.com - May 10 at 1:28 PM |
| Audentes Therapeutics beats by $0.06
seekingalpha.com - May 10 at 10:06 AM |
| Audentes Therapeutics' (BOLD) CEO Matt Patterson on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 10 at 10:06 AM |
 | Audentes Therapeutics: 1Q Earnings Snapshot
www.cnbc.com - May 10 at 10:06 AM |
| Audentes Therapeutics (BOLD) Issues Earnings Results, Beats Estimates By $0.13 EPS
www.americanbankingnews.com - May 9 at 10:46 PM |
| What Should We Expect From Audentes Therapeutics Inc’s (NASDAQ:BOLD) Earnings In The Next Couple Of Years?
finance.yahoo.com - May 9 at 4:10 PM |
| Audentes Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update
finance.yahoo.com - May 9 at 4:10 PM |
| Audentes Therapeutics to Present at the Bank of America Merrill Lynch Health Care Conference 2018
finance.yahoo.com - May 9 at 9:54 AM |
| Audentes Therapeutics (BOLD) Names Natalie Holles President and COO
www.streetinsider.com - May 8 at 9:46 AM |
| Audentes Therapeutics Announces the Promotion of Natalie Holles to President and Chief Operating Officer
finance.yahoo.com - May 8 at 9:46 AM |
| HC Wainwright Analysts Give Audentes Therapeutics (BOLD) a $37.00 Price Target
www.americanbankingnews.com - May 2 at 12:00 PM |
| Audentes Therapeutics to Release First Quarter 2018 Financial Results and Provide Corporate Update on Wednesday, May 9, 2018
finance.yahoo.com - May 2 at 9:46 AM |
| Audentes Therapeutics (BOLD) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - May 2 at 3:14 AM |
| Audentes Therapeutics Announces Presentation of Data at the 21st Annual Meeting of the American Society of Gene and Cell Therapy
finance.yahoo.com - April 30 at 4:07 PM |
| Intellia Therapeutics: An In Vivo Advantage
seekingalpha.com - April 27 at 4:09 PM |
| -$0.81 EPS Expected for Audentes Therapeutics (BOLD) This Quarter
www.americanbankingnews.com - April 24 at 8:08 AM |
| Comparing Audentes Therapeutics (BOLD) & Biogen (BIIB)
www.americanbankingnews.com - April 11 at 1:17 PM |
| Audentes Therapeutics (BOLD) Downgraded to Sell at ValuEngine
www.americanbankingnews.com - April 10 at 7:51 PM |
| First Week of BOLD November 16th Options Trading
www.nasdaq.com - April 10 at 4:07 PM |
| Novartis takeout of AveXis stokes buying in gene therapy players
seekingalpha.com - April 9 at 10:09 AM |
| Audentes Therapeutics (BOLD) Expected to Post Earnings of -$0.81 Per Share
www.americanbankingnews.com - April 7 at 9:55 AM |
| Audentes Therapeutics (BOLD) Coverage Initiated by Analysts at William Blair
www.americanbankingnews.com - April 6 at 10:54 PM |
| Audentes Therapeutics (BOLD) Raised to Hold at ValuEngine
www.americanbankingnews.com - April 5 at 2:14 PM |
| Audentes Therapeutics Inc (BOLD) CEO Matthew R. Patterson Sells 700 Shares
www.americanbankingnews.com - April 4 at 11:37 PM |
| Audentes Therapeutics Inc (BOLD) SVP Sells $303,600.00 in Stock
www.americanbankingnews.com - April 2 at 10:20 PM |
| Audentes Therapeutics Inc (BOLD) VP Sells $234,234.00 in Stock
www.americanbankingnews.com - March 29 at 10:46 PM |
| Insider Selling: Audentes Therapeutics Inc (BOLD) VP Sells 1,900 Shares of Stock
www.americanbankingnews.com - March 28 at 10:48 PM |
| Insider Selling: Audentes Therapeutics Inc (BOLD) Director Sells 48,000 Shares of Stock
www.americanbankingnews.com - March 28 at 10:31 PM |
| Audentes Therapeutics (BOLD) PT Set at $37.00 by HC Wainwright
www.americanbankingnews.com - March 28 at 8:42 PM |
Audentes Therapeutics (NASDAQ:BOLD) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Audentes Therapeutics (NASDAQ:BOLD) Income Statement, Balance Sheet and Cash Flow Statement
Audentes Therapeutics (NASDAQ BOLD) Stock Chart for Thursday, May, 24, 2018
Loading chart…
